

Katie Kazem

Partner



kkazem@cooley.com

+1 703 456 8043

Reston

Public Companies
Mergers and Acquisitions
Capital Markets
CooleyREG

Katie Kazem's practice focuses on corporate and securities law and includes the general representation of both public and private companies, with particular experience in advising European life sciences companies on IPOs, capital raising, SEC compliance and corporate governance. She has experience working on M&A, public offerings and venture capital financings.

Representative company-side and underwriter-side public offerings:

- Valneva SE – \$107.6 million IPO, \$102.0 million follow-on offering
- Nanobiotix SA – \$113.3 million IPO
- Genfit SA - \$155.4 million IPO
- Innate Pharma SA - \$79.1 million IPO
- MaxCyte, Inc. - \$201.8 million IPO
- Renalytix plc - \$74.3 million IPO
- Landos Biopharma – \$100 million IPO
- 2U – \$119.3 million IPO
- Aclaris Therapeutics – \$105 million follow-on offering
- Autolus Therapeutics – \$150 million IPO
- Biohaven Pharmaceuticals - \$193.5 million IPO
- Clearside – aggregate \$77.4 million IPO and follow-on offering
- Entasis Therapeutics – \$75 million IPO
- Erytech – \$125 million IPO

Education

George Mason University, Antonin Scalia Law School
JD, 2010

George Mason University, School of Public Policy
MA, 2007

College of William & Mary

BA, 2003

Admissions & Credentials

Virginia

District of Columbia